Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer
- 作者：Yosra Bouraoui ; Mó ; nica Ricote ; Ignacio Garcí ; a-Tuñ ; ó ; n ; Gonzalo Rodriguez-Berriguete ; Mounir Touffehi ; Nawfel Ben Rais ; Benito Fraile ; Ricardo Paniagua ; Ridha Oueslati ; Mar Royuela
- 关键词：Prostate cancer ; TNF-
//www.sciencedirect.com/scidirimg/entities/204e.gif" alt="greek small letter alpha" title="greek small letter alpha" border="0"> ; IL-6 ; IL-1 ; PSA ; Biochemical markers ; Immunochemistry ; Benign prostatic hyperplasia ; Tumo
- 刊名：Cancer Detection and Prevention
- 出版年：2008
- 期刊代码：163_0361090x
- 类别：bio
- 出版时间：2008
- 卷：32
- 期：1
- 页码：23-32
- 文件大小：7057 K
摘要
Background: The aim of this study was to relate the expression, analyzed by Western blot and immunohistochemistry, of several pro-inflammatory cytokines, including IL-1, IL-6 and TNF-
, with serum levels of prostate-specific antigen (PSA) in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression. We are also discussing the possible use of these cytokines as a potential therapeutic target. Methods: The study was carried out in 5 normal, 25 benign prostatic hyperplastic (BPH) and 17 cancerous human prostates (PC). Immunohistochemical and Western blot analysis were performed. Serum levels of PSA were assayed by an immulite autoanalyzer. Results: The most relevant results showed that in BPH, IL-1, IL-6 and tumor necrosis factor (TNF) were only expressed in patients with PSA serum levels of 0–4 or 4–20 ng/ml, but not in the group >20 ng/ml. In PC these cytokines were only expressed in patients with PSA serum levels >4 ng/ml. Conclusions: In PC there was an association between the high expression of pro-inflammatory cytokines (TNF, IL-6, IL-1), elevated serum levels of PSA and cancer progression. A better understanding of the biologic mechanism of this association may provide new targets for therapy in these patients.
, with serum levels of prostate-specific antigen (PSA) in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression. We are also discussing the possible use of these cytokines as a potential therapeutic target. Methods: The study was carried out in 5 normal, 25 benign prostatic hyperplastic (BPH) and 17 cancerous human prostates (PC). Immunohistochemical and Western blot analysis were performed. Serum levels of PSA were assayed by an immulite autoanalyzer. Results: The most relevant results showed that in BPH, IL-1, IL-6 and tumor necrosis factor (TNF) were only expressed in patients with PSA serum levels of 0–4 or 4–20 ng/ml, but not in the group >20 ng/ml. In PC these cytokines were only expressed in patients with PSA serum levels >4 ng/ml. Conclusions: In PC there was an association between the high expression of pro-inflammatory cytokines (TNF, IL-6, IL-1), elevated serum levels of PSA and cancer progression. A better understanding of the biologic mechanism of this association may provide new targets for therapy in these patients.